Pêche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi M C
Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 643 and Institut de Transplantation et de Recherche en Transplantation (ITERT), Nantes, Cedex 1 France.
Am J Transplant. 2006 Jul;6(7):1541-50. doi: 10.1111/j.1600-6143.2006.01344.x.
Exosomes are MHC-bearing vesicles secreted by a wide array of cells. We have previously shown that donor-haplotype exosomes from bone marrow dendritic cells (DCs) injected before transplantation significantly prolong heart allograft survival in congenic and fully MHC-mismatched Lewis rats. Here we show that donor exosomes administered after transplantation are similarly able to prolong allograft survival, however, without inducing tolerance. We therefore tested the effect of exosomes combined with short-term LF 15-0195 (LF) treatment, which blocks the maturation of DCs, so that donor-MHC antigens from exosomes could be presented in a more tolerogenic environment. LF treatment does not preclude the development of a strong antidonor cellular response, and while LF, but not exosome, treatment inhibits the antidonor humoral response and decreases leukocyte graft infiltration, allografts from LF-treated recipients were either acutely or strongly chronically rejected. Interestingly, when combined with LF treatment, exosomes induced a donor-specific allograft tolerance characterized by a strong inhibition of the antidonor proliferative response. This donor-specific tolerance was transferable to naïve allograft recipients. Moreover, exosomes/LF treatment prevented or considerably delayed the appearance of chronic rejection. These results suggest that under LF treatment, presentation of donor-MHC antigens (from exosomes) can induce regulatory responses that are able to modulate allograft rejection and to induce donor-specific allograft tolerance.
外泌体是由多种细胞分泌的携带主要组织相容性复合体(MHC)的囊泡。我们之前已经表明,在移植前注射的来自骨髓树突状细胞(DCs)的供体单倍型外泌体能够显著延长同基因和完全MHC不匹配的Lewis大鼠心脏同种异体移植的存活时间。在此我们表明,移植后给予供体外泌体同样能够延长同种异体移植的存活时间,然而,不会诱导免疫耐受。因此,我们测试了外泌体与短期LF 15 - 0195(LF)治疗相结合的效果,LF可阻断DCs的成熟,从而使外泌体中的供体MHC抗原能够在更具耐受性的环境中呈递。LF治疗并不排除强烈的抗供体细胞反应的发生,并且虽然LF治疗(而非外泌体治疗)抑制了抗供体体液反应并减少了白细胞向移植物的浸润,但来自接受LF治疗的受体的同种异体移植物要么被急性排斥,要么被强烈地慢性排斥。有趣的是,当与LF治疗相结合时,外泌体诱导了以强烈抑制抗供体增殖反应为特征的供体特异性同种异体移植耐受。这种供体特异性耐受可转移至未接触过抗原的同种异体移植受体。此外,外泌体/LF治疗预防或显著延迟了慢性排斥的出现。这些结果表明,在LF治疗下,(来自外泌体的)供体MHC抗原的呈递能够诱导调节性反应,从而能够调节同种异体移植排斥并诱导供体特异性同种异体移植耐受。